Celgene Corporation ((CELG)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Celgene Corporation is spearheading a clinical study titled A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma. The primary aim is to assess the safety and determine the optimal dose of mezigdomide when used with elranatamab for treating relapsed and refractory multiple myeloma, a significant concern in oncology.
Intervention/Treatment: The study is testing a combination of drugs: Elranatamab, Mezigdomide, and Dexamethasone. These are administered in specified doses to evaluate their combined efficacy and safety in treating multiple myeloma.
Study Design: This interventional study is randomized and follows a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused, aiming to establish a safe and effective treatment regimen.
Study Timeline: The study is set to begin on July 15, 2025, with the primary completion and estimated completion dates yet to be disclosed. The latest update was submitted on July 7, 2025, indicating the study is in the preparatory phase and not yet recruiting participants.
Market Implications: The initiation of this study could positively influence Celgene’s stock performance as it demonstrates ongoing innovation in cancer treatment. This could enhance investor confidence, especially if preliminary results show promise. Competitors in the oncology space will likely monitor these developments closely, as successful outcomes could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.